Want to see TLSI full AI Analyst Report?
TLSI Stock Chart & Stats
$5.03
$0.10(2.37%)
At close: 4:00 PM EDT
$5.03
$0.10(2.37%)
Day’s Range― - ―
52-Week Range$2.20 - $7.95
Previous Close$4.32
Volume94.41K
Average Volume (3M)171.99K
Market Cap
$306.64M
Enterprise Value$253.39
Total Cash (Recent Filing)$46.29M
Total Debt (Recent Filing)$34.43M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Nov 12, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding61,574,600
10 Day Avg. Volume108,338
30 Day Avg. Volume171,986
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-7.81
Price to Sales (P/S)5.86
P/FCF Ratio-13.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside98.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$52.52M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Gross MarginsRapid revenue growth and consistently high gross margins indicate strong demand and favorable unit economics. If sustained as commercial coverage expands, these characteristics could support operating leverage and improve the long-term profitability potential of the delivery platform.
Clinical And Economic Validation Of PEDDLarge real-world evidence linking PEDD with improved outcomes, higher drug delivery and lower downstream costs strengthens the technology’s clinical and economic case. This may support physician adoption, payer acceptance and partnership opportunities beyond individual procedures.
Broadening Pipeline And Addressable MarketA growing clinical pipeline and expansion into uterine, thyroid and genicular applications reduce dependence on a single indication. Positive early data and multiple trials create several potential avenues for future product adoption, evidence generation and revenue growth.
Bears Say
Persistent Losses And Heavy Cash BurnThe company remains substantially loss-making and consumes significant cash while funding commercialization and development. Without a clear path to breakeven, continued investment may require external financing, increasing dilution or funding risk over the next several quarters.
Stretched And Volatile Balance SheetHigh leverage relative to equity and a history of negative equity limit financial flexibility. This structure can make additional funding more expensive or dilutive and leaves less capacity to absorb execution setbacks while the company scales its commercial platform.
Regulatory Delay And Lowered Revenue GuidanceThe delayed FDA review removes advanced-device revenue from near-term modeling and postpones a potential product expansion. Combined with lower guidance, the delay increases uncertainty around commercialization timing and may slow the revenue scale-up expected from the broader platform.
TriSalus Life Sciences News
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $2.20 and its highest was $7.95 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
TriSalus Life Sciences’s market cap is $306.64M.
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is Nov 12, 2026 which is in 67 days.
How were TriSalus Life Sciences’s earnings last quarter?
TriSalus Life Sciences released its earnings results on Aug 06, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.155 by -$0.005.
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate is -0.12.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 61,574,600 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
TriSalus Life Sciences reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.155. Following the earnings report the stock price went up 15.195%.
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Currently, no hedge funds are holding shares in TLSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TriSalus Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (98.81% Upside)
$10.00 (98.81% Upside)
Blogger Sentiment
Bullish
TLSI Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 38.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
51.14%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
TriSalus Life Sciences
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
TLSI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a major clinical and economic validation of PEDD (landmark real-world study, strong pipeline, meaningful early results in multiple new indications) and a deliberate commercial build intended to capture a large addressable market. Near-term financials were impacted by the deliberate salesforce expansion (temporary revenue disruption, higher operating losses) and a regulatory delay for TriNav Advance that defers some expected second-half revenue. Management positions the investments as strategic and funded by a solid cash balance, with expectations of sustained ramp and commercial momentum through the remainder of 2026 and beyond.View all TLSI earnings summariesTLSI Stock 12 Month Forecast
Average Price Target
$10.00
▲(98.81% Upside)
Technical Analysis
Ownership Overview
28.15% Insiders
6.62% Mutual Funds
17.69% Other Institutional Investors
41.11% Public Companies and
Individual Investors